Esperion Therapeutics Inc (NAS:ESPR)
$ 3.18 -0.010 (-0.31%) Market Cap: 819.47 Mil Enterprise Value: 915.93 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Q2 2020 Esperion Therapeutics Inc Earnings Call Transcript

Aug 10, 2020 / 08:30PM GMT
Release Date Price: $37 (-2.63%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome. (Operator Instructions) Please be advised that today's conference call may be recorded. I would now like to hand the conference call over to Ben Church, Corporate Communications at Esperion. Please go ahead, sir.

Ben Church;Corporate Communications

I'm Ben Church and I'm on the Corporate Communications team here at Esperion. With me on today's call are Tim Mayleben, President and Chief Executive Officer; Mark Glickman, Chief Commercial Officer; and Rick Bartram, Chief Financial Officer.

I want to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to the risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by the cautionary

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot